Filtered By:
Condition: Thrombosis
Procedure: Transplants

This page shows you your search results in order of date. This is page number 16.

Order by Relevance | Date

Total 252 results found since Jan 2013.

Pre-Operative Risk Factors of Bleeding and Stroke During Left Ventricular Assist Device Support An Analysis of More Than 900 HeartMate II Outpatients
ConclusionsThe risk of bleeding and thrombotic events during LVAD support differs by patient demographics, including sex, age, body mass index, and etiology of heart failure. Further studies should focus on the potential of tailored anticoagulation strategies in these subgroups.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 3, 2014 Category: Cardiology Source Type: research

Early elevations in pump power with the HeartMate II left ventricular assist device do not predict late adverse events
Background: The aim of this study was to evaluate the prevalence of early pump power elevation events in patients with the HeartMate II (HMII) and its impact on subsequent development of stroke and pump thrombosis.Methods: We analyzed>45,000 measurements of pump power and pump speed measured during the initial hospitalization period and>12,000 follow-up measurements obtained from 138 consecutive patients implanted with a HMII between January 2009 and December 2012. An early power elevation (PEL) event was defined as power ≥10 W within the first 14 post-operative days. Patients were divided into two groups: those with an ...
Source: The Journal of Heart and Lung Transplantation - March 3, 2014 Category: Transplant Surgery Authors: Christopher T. Salerno, Kartik S. Sundareswaran, Thomas P. Schleeter, Sina L. Moanie, David J. Farrar, Mary Norine Walsh Tags: Featured Articles Source Type: research

Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices
Background: Continuous-flow left ventricular assist devices (LVADs) expose blood cells to high shear stress, potentially resulting in the production of microparticles that express phosphatidylserine (PS+) and promote coagulation and inflammation. In this prospective study, we attempted to determine whether PS+ microparticle levels correlate with clinical outcomes in LVAD-supported patients.Methods: We enrolled 20 patients undergoing implantation of the HeartMate II LVAD (Thoratec Corp, Pleasanton, CA) and 10 healthy controls who provided reference values for the microparticle assays. Plasma was collected before LVAD implan...
Source: The Journal of Heart and Lung Transplantation - January 21, 2014 Category: Transplant Surgery Authors: Angelo Nascimbene, Ruben Hernandez, Joggy K. George, Anita Parker, Angela L. Bergeron, Subhashree Pradhan, K. Vinod Vijayan, Andrew Civitello, Leo Simpson, Maria Nawrot, Vei-Vei Lee, Hari R. Mallidi, Reynolds M. Delgado, Jing Fei Dong, O.H. Frazier Tags: Featured Articles Source Type: research

Use of Left Ventricular Assist Device (HeartMate II): A Singapore Experience
We report our experience with the HeartMate II (HMII) LVAD (Thoratec Corporation, Pleasanton, CA, USA) as a bridge‐to‐heart transplant in our center from 2009 to 2012. This was a retrospective review of 23 consecutive patients who underwent HMII LVAD implantation in our center between May 2009 and December 2012. All patients were classified as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) levels 1 to 3 and underwent LVAD implantation as a bridge‐to‐heart transplant. There were 17 male and 6 female patients. The mean age was 43.6 years old (range 14 to 64). The etiologies of heart fa...
Source: Artificial Organs - January 7, 2014 Category: Transplant Surgery Authors: Choon Pin Lim, Cumaraswamy Sivathasan, Teing Ee Tan, Chong Hee Lim, Ka Lee Kerk, David Kheng Leng Sim Tags: Main Text Article Source Type: research

Renovascular hypertension: A report of 21 cases.
Abstract Renovascular hypertension (RVH) is among the most common forms of secondary hypertension. We studied 21 patients (eight male and 13 female) with RVH who were encountered during a period of 16 years. The average age of the patients was 34.75 years. Trans-renal Doppler ultrasound confirmed the diagnosis of renovascular stenosis (RAS) as the cause of RVH in 95% of the patients. Computed tomography angiography was performed in ten cases, which confirmed the diagnosis in all these cases. Magnetic resonance angiography was performed in only three patients. Renal scintigraphy was performed in 11 patients, with D...
Source: Saudi Journal of Kidney Diseases and Transplantation - January 1, 2014 Category: Urology & Nephrology Authors: Labidi J, Touat D, Abdelghanim K, Ajili F, Ariba YB, Abdelhafidh NB, Louzir B, Othmani S Tags: Saudi J Kidney Dis Transpl Source Type: research

Incidence of increases in pump power use and associated clinical outcomes with an axial continuous-flow ventricular assist device
Left ventricular assist devices (LVADs) have been shown to improve survival in patients with end-stage heart failure. Newer-generation LVADs with continuous-flow mechanics yield lower rates of disabling stroke, infection, and need for device exchange compared with earlier pulsatile-flow devices. It has been hypothesized that an elevation in the pump power may be an early indication of device thrombosis. Our goal was to define the frequency of pump power elevations, evaluate when they happen in relation to device implantation, and determine the rate at which they precede adverse events suggestive of pump thrombosis.
Source: The Journal of Heart and Lung Transplantation - January 1, 2014 Category: Transplant Surgery Authors: Robert J. Steffen, Edward G. Soltesz, Kimberly Miracle, Sangjin Lee, Maria Mountis, Nader Moazami Tags: Research Correspondence Source Type: research

Loss of Mural Cells Leads to Wall Degeneration, Aneurysm Growth, and Eventual Rupture in a Rat Aneurysm Model Basic Sciences
Conclusions— In the presented experimental setting, complete loss of mural cells acts as a driving force for aneurysm growth and rupture. The findings suggest that aneurysms missing mural cells are incapable to organize a luminal thrombus, leading to recanalization, increased inflammatory reaction, severe wall degeneration, and eventual rupture.
Source: Stroke - December 23, 2013 Category: Neurology Authors: Marbacher, S., Marjamaa, J., Bradacova, K., von Gunten, M., Honkanen, P., Abo-Ramadan, U., Hernesniemi, J., Niemela, M., Frosen, J. Tags: Basic Sciences Source Type: research

Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices
Conclusions: In the setting of LVAD thrombosis, thrombolytic therapy is an alternate treatment strategy in a subset of patients. Candidacy for this alternate procedure must carefully weigh the risks of complications, including hemorrhage and thromboembolism.
Source: Journal of Cardiac Failure - December 19, 2013 Category: Cardiology Authors: Kelly Schlendorf, Chetan B. Patel, Thomas Gehrig, Todd L. Kiefer, G. Michael Felker, Adrian F. Hernandez, Laura J. Blue, Carmelo A. Milano, Joseph G. Rogers Tags: Clinical Investigations Source Type: research

Hemolysis: A harbinger of adverse outcome after left ventricular assist device implant
Background: The clinical relevance of elevated serum markers of hemolysis during left ventricular assist device (LVAD) support has not been fully ascertained.Methods: Lactate dehydrogenase (LDH) and serum free hemoglobin (sfHg) values were tallied monthly in 182 patients on HeartMate II (Thoratec, Pleasanton, CA) LVAD support. Peak values for each marker were identified, and 2 hemolysis definitions were applied to the cohort: Hemolysis according to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) criteria (sfHg> 40 mg/dl with signs/symptoms) and/or hemolysis defined by an LDH ≥ 600 IU/liter ...
Source: The Journal of Heart and Lung Transplantation - December 2, 2013 Category: Transplant Surgery Authors: Jennifer A. Cowger, Matthew A. Romano, Palak Shah, Neha Shah, Vivek Mehta, Jonathan W. Haft, Keith D. Aaronson, Francis D. Pagani Tags: Featured Articles Source Type: research

Hormone Therapy in Women After Heart Transplantation
Conclusions: HT is not associated with poor outcome or adverse effects in female heart transplant patients after age 35 years. However, a larger cohort of patients is necessary to confirm these observations.
Source: Transplantation Proceedings - November 1, 2013 Category: Transplant Surgery Authors: L.C. Kobashigawa, M. Hamilton, M. Rafiei, L. Stern, C.N. Bairey Merz Tags: Thoracic Transplantation Source Type: research

Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation
Conclusions: LMWH in the setting of LVAD shows rapid and constant biologic efficacy. Anti-coagulation with LMWH appears feasible after LVAD implantation. These findings support further evaluation of LMWH as an alternative to unfractionated heparin in this patient cohort.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: Sigrid E. Sandner, Julia Riebandt, Thomas Haberl, Stephane Mahr, Angela Rajek, Heinrich Schima, George M. Wieselthaler, Guenther Laufer, Daniel Zimpfer Tags: Featured Articles Source Type: research

Carotid-bulb thrombus and continuous-flow left ventricular assist devices: A novel observation
The continuous-flow left ventricular assist device (LVAD) has emerged as a clinically important treatment strategy for patients with advanced-stage heart failure. However, LVADs are not without associated neurologic complications, including stroke. In one review, the incidence of stroke (both ischemic and hemorrhagic) with the HeartMate II (HM II; Thoratec, Pleasanton, CA) ranged from 2% to 18%. In another recent single-center study, the incidence was 10%. In that study, previous stroke, persistent malnutrition and inflammation, severity of heart failure and post-LVAD infections were associated with neurologic complications.
Source: The Journal of Heart and Lung Transplantation - October 28, 2013 Category: Transplant Surgery Authors: John T. Reul, George J. Reul, O.H. Frazier Tags: Research Correspondence Source Type: research

Enhanced recovery from chronic ischemic injury by bone marrow cells in a rat model of ischemic stroke.
This study provides valuable insights into the effect of BMC transplantation in the chronic ischemic brain, which lead to the development of effective therapy for chronic stroke patients who currently lack satisfactory therapeutic options. PMID: 24152766 [PubMed - as supplied by publisher]
Source: Cell Transplantation - October 22, 2013 Category: Cytology Authors: Yoo J, Seo JJ, Eom JH, Hwang DY Tags: Cell Transplant Source Type: research

Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years?
Abstract Since the pioneering studies by Eschbach et al in 1987, erythropoiesis-stimulating agents (ESAs) have become the mainstay of anemia therapy in chronic kidney disease (CKD) patients. The introduction of ESAs 25 years ago markedly improved the lives of many patients with CKD, who until then had severe, often transfusion-dependent anemia. However, randomized controlled trials demonstrate an increased risk for cardiovascular events such as stroke, thrombosis, and death at nearly normal hemoglobin concentrations and higher ESA doses in CKD. By contrast, kidney transplant recipients may represent a unique popu...
Source: J Formos Med Assoc - September 30, 2013 Category: Journals (General) Authors: Hung SC, Lin YP, Tarng DC Tags: J Formos Med Assoc Source Type: research